AmritaGen, Inc
About Us
AmritaGen is a mechanism-based neurology related neuro-glia-vascular (NGV) functional network focused startup. AmritaGen is pioneering the discovery and development of a new gene therapy for delivering combination of drugs for the treatment of NGV dysfunction in mild cognitive impairment (MCI) –a prodromal of Alzheimer’s disease (AD), and sporadic AD (sAD)) patients.
AmritaGen Solution
To overcome many of these problems related to AAV-mediated gene therapy:
- AmritaGen developed a proprietary gene delivery system that involves generating genetically engineered mesenchymal stem cell (MSC) derived exosome (we call it cap-exosomes), that display in the membrane of exosomes outwardly various functional AAV capsid domain specific peptide.
- Systemic delivery of these cap-exosomes loaded with green fluorescent protein (GFP) gene in mice showed that cap-exosomes-GFP-gene particles have ability to intracellular trafficking (endosomal escaping), nuclear entry, and blood brain barrier (BBB) specific endothelial cell crossing to enter brain cells and express GFP protein.
- Pre-clinical studies by Cap-exosomes mediated antisense miR-34a gene therapy in sAD.
